Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


Inhibitor of FLT3 and ABC proteins
ENZ-CHM154-0001 1 mg 93.00 USD
ENZ-CHM154-0005 5 mg 161.00 USD
Do you need bulk/larger quantities?
Quizartinib (AC220) is a second-generation FLT3 inhibitor that has shown promising activity in Phase II clinical trials. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Recently, AC220 has also been shown to be an effective inhibitor of ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5 µM and from 0.5 to 10 µM, respectively, and inhibited [125I]-IAAP photolabeling of ABCG2 and ABCB1 with IC50 values of 0.07 and 3.3 µM, respectively.

Product Details

Alternative Name:AC-220, 1-(5-tert-Butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
Purity:≥97% (HPLC)
Identity:Determined by EM-MS, NMR
Appearance:White powder.
Solubility:Soluble in DMSO (33mg/ml) or ethanol (0.5mg/ml).
Short Term Storage:+4°C
Long Term Storage:-20°C
Regulatory Status:RUO - Research Use Only
ENZ-CHM154 structure
Please mouse over
ENZ-CHM154 structure

Product Literature References

PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers: A.J. Dellomo, et al.; Transl. Oncol. 15, 101283 (2021), Abstract;

Related Literature

Product Flyers
Detect Activity of Major ABC Transporter Proteins
Detect Activity of Major ABC Transporter Proteins
Download as PDF

All new literature pieces

Recommend this page

Keep in touch

©2022 Enzo Life Sciences, Inc.,